{"id":354157,"date":"2025-08-28T11:36:39","date_gmt":"2025-08-28T11:36:39","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/news-events\/data\/how-to-buy-rhythm-pharmaceuticals\/"},"modified":"2025-08-28T11:36:39","modified_gmt":"2025-08-28T11:36:39","slug":"how-to-buy-rhythm-pharmaceuticals","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/en\/news-events\/signal\/how-to-buy-rhythm-pharmaceuticals\/","title":{"rendered":"How to buy Rhythm Pharmaceuticals, Inc. (RYTM) shares – Investment in Rhythm Pharmaceuticals, Inc. (RYTM) stock"},"content":{"rendered":"
text<\/div><\/div>","protected":false},"excerpt":{"rendered":"

text<\/p>\n","protected":false},"author":129,"featured_media":334072,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-354157","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"How to Buy Rhythm Pharmaceuticals, Inc. (RYTM) Shares - Investment in Rhythm Pharmaceuticals, Inc. (RYTM) Stock","h1_source":{"label":"H1","type":"text","formatted_value":"How to Buy Rhythm Pharmaceuticals, Inc. (RYTM) Shares - Investment in Rhythm Pharmaceuticals, Inc. (RYTM) Stock"},"description":"Learn how to buy Rhythm Pharmaceuticals, Inc. (RYTM) shares with our comprehensive investment guide. Discover current stock performance, price forecasts, and strategic insights for investing in this innovative biopharmaceutical company.","description_source":{"label":"Description","type":"textarea","formatted_value":"Learn how to buy Rhythm Pharmaceuticals, Inc. (RYTM) shares with our comprehensive investment guide. Discover current stock performance, price forecasts, and strategic insights for investing in this innovative biopharmaceutical company."},"intro":"Imagine owning a piece of a company that's literally changing lives through cutting-edge genetic obesity treatments. Rhythm Pharmaceuticals isn't just another biotech stock\u2014it's a precision medicine pioneer with explosive growth potential. For new investors looking beyond traditional sectors, RYTM offers a fascinating entry point into the high-growth rare disease market with recent FDA breakthroughs creating massive momentum.","intro_source":{"label":"Intro","type":"text","formatted_value":"Imagine owning a piece of a company that's literally changing lives through cutting-edge genetic obesity treatments. Rhythm Pharmaceuticals isn't just another biotech stock\u2014it's a precision medicine pioneer with explosive growth potential. For new investors looking beyond traditional sectors, RYTM offers a fascinating entry point into the high-growth rare disease market with recent FDA breakthroughs creating massive momentum."},"body_html":"

\ud83d\udcc8 RYTM Stock Analysis: Current Price and Critical Dates<\/h2>

As of August 28, 2025, Rhythm Pharmaceuticals, Inc. (RYTM) trades at $99.20<\/strong> per share. But mark your calendar\u2014November 4, 2025<\/strong> is your next major catalyst. That's when Rhythm releases its Q3 earnings, and if history repeats itself, this could be another explosive moment.<\/p>

How FDA News Moves RYTM Stock<\/h3>

The pattern is clear: regulatory news equals price movement. When Rhythm announced FDA acceptance of their sNDA for setmelanotide on August 20, 2025<\/a>, the stock jumped from $98.70 to $103.27 within days\u2014a 4.6% surge.<\/p>

Here's how recent milestones have moved the needle:<\/p>
Date<\/th>Event<\/th>Price Impact<\/th>Duration<\/th><\/tr> <\/thead>
Aug 20, 2025<\/td>FDA sNDA Acceptance<\/td>+4.6%<\/td>2 days<\/td><\/tr>
Jul 9, 2025<\/td>Bivamelagon Phase 2 Results<\/td>+25.4%<\/td>1 week<\/td><\/tr>
Jul 10, 2025<\/td>$175M Public Offering<\/td>-3.2%<\/td>1 day<\/td><\/tr>
Q2 2025 Earnings<\/td>Commercial Revenue Beat<\/td>+8.1%<\/td>3 days<\/td><\/tr> <\/tbody> <\/table>

The lesson? FDA catalysts create immediate momentum, while dilution events cause short-term dips that often become buying opportunities.<\/p>

6-Month Price Journey: From $55 to $100+<\/h3>

Rhythm's stock has delivered an incredible 82.74%<\/strong> year-to-date return according to MarketBeat data<\/a>. Here's the monthly breakdown:<\/p>

March 2025<\/strong>: Around $55 (post-winter consolidation) May 2025<\/strong>: $75-80 (Phase 2 trial anticipation) July 2025<\/strong>: $85+ (trial results and offering) August 2025<\/strong>: $99-103 (FDA catalyst peak)<\/p>

The driving forces? Explosive clinical trial results showing up to 9.3% BMI reduction with bivamelagon and that crucial FDA priority review designation for December 2025.<\/p> [cta_green text=\"Start trading\"]

\ud83d\udd2e Price Forecast: 2025-2030 Outlook<\/h2>

Short-Term (Next 3-6 Months)<\/h3>

With the December 20, 2025 PDUFA date approaching, analysts project RYTM could reach $110-120<\/strong> if approval is granted. The current average 12-month target sits at $80.83<\/strong> according to 18 analysts<\/a>, but this seems conservative given recent momentum.<\/p>

Verdict<\/strong>: STRONG BUY - The FDA catalyst window creates exceptional upside potential.<\/p>

Medium-Term (2026)<\/h3>

Expect $130-150<\/strong> range as commercial expansion accelerates. Revenue is projected to grow 65.62% to $310M next year, and if bivamelagon advances to Phase III successfully, the valuation could expand significantly.<\/p>

Long-Term (2028-2030)<\/h3>

By 2028, with multiple approved indications and international expansion, $200-250<\/strong> seems achievable. By 2030, if Rhythm becomes the dominant MC4R therapy company, $300+<\/strong> isn't unrealistic given the addressable market in rare obesity diseases.<\/p>

\u26a0\ufe0f Risk Assessment: What Could Go Wrong?<\/h2>

High-Impact Risks<\/h3>

Regulatory Rejection<\/strong>: The December FDA decision is binary\u2014approval sends shares soaring, rejection could drop them 30-50%.<\/p>

Clinical Setbacks<\/strong>: Phase III trials for bivamelagon begin soon\u2014any safety issues would be devastating.<\/p>

Cash Burn<\/strong>: Despite the $175M raise, Rhythm still burns ~$188M annually. They'll need additional funding within 12-18 months.<\/p>

Moderate Risks<\/h3>

Competition<\/strong>: Larger pharma companies are developing competing MC4R agonists.<\/p>

Pricing Pressure<\/strong>: Payers may push back on premium pricing for rare disease treatments.<\/p>

\ud83d\udfe2 Positive Signals: Why Investors Are Excited<\/h2>

Clinical Triumphs<\/h3>

The Phase 2 bivamelagon data<\/a> was exceptional\u20149.3% BMI reduction versus placebo's 2.2% increase. This isn't marginal improvement; it's potentially practice-changing.<\/p>

Market Exclusivity<\/h3>

Orphan drug status provides 7 years of market exclusivity\u2014a massive competitive moat.<\/p>

Revenue Acceleration<\/h3>

Q2 2025 showed 43.84%<\/strong> revenue growth to $187M annually. The growth trajectory is steep and sustainable.<\/p>

\ud83c\udfaf Beginner Trader Action Plan<\/h2>

Today's Reality<\/strong>: RYTM sits at an interesting juncture\u2014just below recent highs but with massive FDA catalyst approaching.<\/p>

What to Do Now<\/strong>:<\/p>

  1. Scale In Gradually<\/strong>: Don't go all-in at once. Buy 25% now, 25% if it dips to $90, 50% after Q3 earnings if story remains intact<\/li>
  2. Set Alert for November 4<\/strong>: Q3 earnings will show if commercial momentum continues<\/li>
  3. Prepare for December Volatility<\/strong>: FDA decisions create extreme moves\u2014have both profit-taking and averaging-down plans ready<\/li> <\/ol>

    Humorous Take<\/strong>: \"Trading RYTM is like watching a medical drama\u2014each episode ends with a cliffhanger that either saves the patient or requires emergency surgery. Bring your popcorn and your risk management!\"<\/p>

    \u2705 How to Buy Rhythm Pharmaceuticals, Inc. (RYTM) Shares - Step by Step<\/h2>
    Step<\/th>Action<\/th>Why This Matters<\/th><\/tr> <\/thead>
    1<\/td>Choose Your Platform<\/td>Ensure it offers NASDAQ stocks and has reasonable commission structure<\/td><\/tr>
    2<\/td>Fund Your Account<\/td>Start with an amount you're comfortable risking\u2014biotech is volatile<\/td><\/tr>
    3<\/td>Search \"RYTM\"<\/td>Use the ticker symbol, not the company name<\/td><\/tr>
    4<\/td>Select Order Type<\/td>Use limit orders to control entry price\u2014avoid market orders in volatile stocks<\/td><\/tr>
    5<\/td>Review and Execute<\/td>Double-check share quantity and order details before confirming<\/td><\/tr> <\/tbody> <\/table>

    \ud83d\udca1 Why Pocket Option Makes RYTM Investing Accessible<\/h2>

    For new investors drawn to Rhythm's story but hesitant about the volatility, Pocket Option offers the perfect testing ground. With a minimum deposit of just $5<\/strong>, you can take a small position without overexposing your portfolio. The platform's 1-minute KYC process<\/strong> means you can react quickly to breaking news\u2014crucial for biotech stocks where hours matter.<\/p>

    What really sets Pocket Option apart for RYTM trading:<\/p>